PE20220400A1 - Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio - Google Patents
Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorioInfo
- Publication number
- PE20220400A1 PE20220400A1 PE2021001766A PE2021001766A PE20220400A1 PE 20220400 A1 PE20220400 A1 PE 20220400A1 PE 2021001766 A PE2021001766 A PE 2021001766A PE 2021001766 A PE2021001766 A PE 2021001766A PE 20220400 A1 PE20220400 A1 PE 20220400A1
- Authority
- PE
- Peru
- Prior art keywords
- prevention
- treatment
- respiratory tract
- tract infection
- subunit vaccine
- Prior art date
Links
- 206010057190 Respiratory tract infections Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229940031626 subunit vaccine Drugs 0.000 title 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 229940125575 vaccine candidate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175413 | 2019-05-20 | ||
| PCT/EP2020/063973 WO2020234300A1 (en) | 2019-05-20 | 2020-05-19 | A subunit vaccine for treatment or prevention of a respiratory tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220400A1 true PE20220400A1 (es) | 2022-03-22 |
Family
ID=66685352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001766A PE20220400A1 (es) | 2019-05-20 | 2020-05-19 | Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12162907B2 (enExample) |
| EP (1) | EP3972639A1 (enExample) |
| JP (1) | JP2022533318A (enExample) |
| KR (1) | KR20220010478A (enExample) |
| CN (1) | CN114127101A (enExample) |
| AU (1) | AU2020277661A1 (enExample) |
| BR (1) | BR112021021637A2 (enExample) |
| CA (1) | CA3138064A1 (enExample) |
| CL (1) | CL2021002819A1 (enExample) |
| CO (1) | CO2021014694A2 (enExample) |
| EC (1) | ECSP21079178A (enExample) |
| GB (1) | GB2598494B (enExample) |
| IL (1) | IL287099A (enExample) |
| MX (1) | MX2021013111A (enExample) |
| MY (1) | MY208001A (enExample) |
| PE (1) | PE20220400A1 (enExample) |
| PH (1) | PH12021552736A1 (enExample) |
| SA (1) | SA521430813B1 (enExample) |
| SG (1) | SG11202110646PA (enExample) |
| WO (1) | WO2020234300A1 (enExample) |
| ZA (1) | ZA202106883B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| US12018054B2 (en) | 2017-04-13 | 2024-06-25 | Valneva Austria Gmbh | Multivalent OspA polypeptides and methods and uses relating thereto |
| EP3972639A1 (en) | 2019-05-20 | 2022-03-30 | Valneva SE | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| CA3174599A1 (en) | 2020-04-09 | 2021-10-14 | Robert Schlegl | Improvements in vaccine formulations for medical use |
| EP4132950A1 (en) | 2020-04-09 | 2023-02-15 | Valneva Austria GmbH | Compositions comprising three ospa fusion proteins for medical use |
| KR102860080B1 (ko) | 2020-10-09 | 2025-09-15 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 융합전-안정화된 hmpv f 단백질 |
| AU2021380755A1 (en) | 2020-11-13 | 2023-06-22 | Icosavax, Inc. | Protein-based nanoparticle vaccine for metapneumovirus |
| KR20230167017A (ko) | 2021-04-09 | 2023-12-07 | 발네바 에스이 | 인간 메타뉴모 바이러스 백신 |
| US20240335523A1 (en) * | 2021-08-05 | 2024-10-10 | The Regents Of The University Of California | Glycoengineered Foldon Domains and Related Compositions and Methods |
| EP4448802A1 (en) * | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| US20240252614A1 (en) | 2023-01-18 | 2024-08-01 | Pfizer Inc. | Vaccines against respiratory diseases |
| CN121263205A (zh) * | 2023-02-06 | 2026-01-02 | 塞维卡有限责任公司 | 修饰的piv5疫苗载体：制造方法和用途 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025201243A1 (zh) * | 2024-03-25 | 2025-10-02 | 中国医学科学院医学生物学研究所 | 重组呼吸道合胞病毒融合前f蛋白突变体和其用途 |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN119176858B (zh) * | 2024-11-22 | 2026-01-09 | 北京华诺泰生物医药科技有限公司 | 一种重组人偏肺病毒融合前f蛋白纯化方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5547871A (en) | 1993-01-25 | 1996-08-20 | American Cyanamid Company | Heterologous signal sequences for secretion of insect controlling proteins |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| RU2413520C2 (ru) | 2000-06-08 | 2011-03-10 | Интерселл Аг | Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| CA2418854A1 (en) | 2000-08-17 | 2002-02-21 | Jorg Fritz | A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| US8715922B2 (en) * | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
| WO2002094845A2 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Method for stabilising of nucleic acids |
| AU2002358616A1 (en) | 2001-12-07 | 2003-06-17 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| EP1608402B1 (en) | 2003-03-24 | 2010-10-20 | Intercell AG | Improved vaccines |
| CN101410519B (zh) | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| EP2445527A2 (en) | 2009-06-24 | 2012-05-02 | ID Biomedical Corporation of Quebec | Vaccine |
| US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
| CN102145167A (zh) * | 2010-02-05 | 2011-08-10 | 重庆医科大学附属儿童医院 | 重组人类偏肺病毒疫苗 |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP3269386B1 (en) | 2011-12-06 | 2022-09-14 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
| CN105408348B (zh) * | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| CL2013002829A1 (es) | 2013-10-01 | 2014-04-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. |
| WO2016103238A1 (en) | 2014-12-24 | 2016-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus f proteins and their use |
| CA2996762A1 (en) * | 2015-08-31 | 2017-03-09 | Technovax, Inc. | Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| US10961283B2 (en) | 2016-06-27 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| WO2019092002A1 (en) * | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
| EP3972639A1 (en) | 2019-05-20 | 2022-03-30 | Valneva SE | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| KR20230167017A (ko) | 2021-04-09 | 2023-12-07 | 발네바 에스이 | 인간 메타뉴모 바이러스 백신 |
-
2020
- 2020-05-19 EP EP20726137.1A patent/EP3972639A1/en active Pending
- 2020-05-19 BR BR112021021637A patent/BR112021021637A2/pt unknown
- 2020-05-19 PE PE2021001766A patent/PE20220400A1/es unknown
- 2020-05-19 PH PH1/2021/552736A patent/PH12021552736A1/en unknown
- 2020-05-19 MX MX2021013111A patent/MX2021013111A/es unknown
- 2020-05-19 AU AU2020277661A patent/AU2020277661A1/en active Pending
- 2020-05-19 MY MYPI2021005570A patent/MY208001A/en unknown
- 2020-05-19 CA CA3138064A patent/CA3138064A1/en active Pending
- 2020-05-19 KR KR1020217034461A patent/KR20220010478A/ko not_active Ceased
- 2020-05-19 JP JP2021564088A patent/JP2022533318A/ja active Pending
- 2020-05-19 GB GB2114836.6A patent/GB2598494B/en active Active
- 2020-05-19 US US17/606,811 patent/US12162907B2/en active Active
- 2020-05-19 SG SG11202110646PA patent/SG11202110646PA/en unknown
- 2020-05-19 CN CN202080030901.9A patent/CN114127101A/zh active Pending
- 2020-05-19 WO PCT/EP2020/063973 patent/WO2020234300A1/en not_active Ceased
-
2021
- 2021-09-17 ZA ZA2021/06883A patent/ZA202106883B/en unknown
- 2021-10-07 IL IL287099A patent/IL287099A/en unknown
- 2021-10-25 EC ECSENADI202179178A patent/ECSP21079178A/es unknown
- 2021-10-26 CL CL2021002819A patent/CL2021002819A1/es unknown
- 2021-10-29 CO CONC2021/0014694A patent/CO2021014694A2/es unknown
- 2021-11-10 SA SA521430813A patent/SA521430813B1/ar unknown
-
2023
- 2023-10-24 US US18/493,004 patent/US12162909B2/en active Active
-
2024
- 2024-10-31 US US18/932,700 patent/US20250171501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020234300A1 (en) | 2020-11-26 |
| PH12021552736A1 (en) | 2022-07-11 |
| MX2021013111A (es) | 2021-11-17 |
| MY208001A (en) | 2025-04-03 |
| CO2021014694A2 (es) | 2022-01-17 |
| US12162909B2 (en) | 2024-12-10 |
| SG11202110646PA (en) | 2021-10-28 |
| IL287099A (en) | 2021-12-01 |
| GB2598494B (en) | 2024-07-24 |
| JP2022533318A (ja) | 2022-07-22 |
| KR20220010478A (ko) | 2022-01-25 |
| SA521430813B1 (ar) | 2024-04-27 |
| ECSP21079178A (es) | 2021-11-30 |
| BR112021021637A2 (pt) | 2021-12-21 |
| GB202114836D0 (en) | 2021-12-01 |
| CN114127101A (zh) | 2022-03-01 |
| ZA202106883B (en) | 2022-07-27 |
| EP3972639A1 (en) | 2022-03-30 |
| US20250171501A1 (en) | 2025-05-29 |
| CL2021002819A1 (es) | 2022-07-08 |
| AU2020277661A1 (en) | 2021-10-21 |
| US20220185847A1 (en) | 2022-06-16 |
| GB2598494A (en) | 2022-03-02 |
| US20240067681A1 (en) | 2024-02-29 |
| US12162907B2 (en) | 2024-12-10 |
| CA3138064A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220400A1 (es) | Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio | |
| CO2018002060A2 (es) | Compuestos farmacéuticos | |
| BR112017005917A2 (pt) | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana | |
| MX375170B (es) | Compuestos de amida para el tratamiento de vih. | |
| MX364942B (es) | Peptidos antimicrobianos. | |
| PE20151867A1 (es) | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| MX2015012397A (es) | Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada. | |
| MX2017010506A (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| CY1118399T1 (el) | Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c | |
| BR112017003242A2 (pt) | composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto. | |
| CL2017000714A1 (es) | Composiciones farmacéuticas de acción prolongada | |
| MX378266B (es) | Inhibidores de gingipaina de lisina. | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| MX2017009094A (es) | Derivado de polimixina y usos del mismo. | |
| MX2017002385A (es) | Metodos y reactivos para la prevencion y/o el tratamiento de infecciones. | |
| CO2020008887A2 (es) | Inhibidores de pi4kiiiβ | |
| BR112018067554A2 (pt) | formulações de testosterona e métodos de tratamento com as mesmas | |
| UY36851A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| MX364704B (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| CL2017001161A1 (es) | Composiciones farmacéuticas de acción prolongada para la hepatitis c | |
| CL2017001160A1 (es) | Combinación de composiciones de acción prolongada y métodos para la hepatitis c |